Previous 10 | Next 10 |
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Protagonist Therapeutics (NASDAQ: PTGX ) stock is rocketing higher on Monday thanks to an update from the U.S. Food and Drug Administration (FDA) concerning rusfertide clinical studies. Source: JHVEPhoto / Shutter...
Protagonist Therapeutics (NASDAQ:PTGX) +89% after FDA removes clinical hold on rusfertide program Flexion Therapeutics (NASDAQ:FLXN) +73% Pacira Therapeutics acquires Flexion Therapeutics for $8.50 per share in cash plus one CVR Adamas Pharmaceuticals (NASDAQ:ADMS) +7...
Protagonist Therapeutics Announces Removal of FDA Clinical Hold on the Rusfertide Clinical Development Program All ongoing clinical trials of rusfertide to resume dosing Phase 3 registrational trial planned to commence in the first quarter of 2022 Conference call schedul...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips In the game of investing, there are protagonists and antagonists. and right now, Wall Street is antagonizing Protagonist Therapeutics (NASDAQ: PTGX ) stock as definitely out of favor. Source: Shutterstock P...
Protagonist Therapeutics Announces Data from Phase 2 Rusfertide Study in Hereditary Hemochromatosis Selected for Oral Presentation at the Annual AASLD Meeting PR Newswire NEWARK, Calif. , Oct. 4, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: P...
Today, we revisit Protagonist Therapeutics for the first time in over a year and a half. The stock has cratered in recent trading sessions after the FDA put a clinical hold on a key study. Is this dip buyable? We attempt to answer that question in the questions below. For fu...
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Protagonist Therapeutics, Inc. (“Protagonist” or the “Company”) (NASDAQ: PTGX) on behalf of Protagonist stockholders. Our inves...
Gainers: Helbiz (NASDAQ:HLBZ) +128%. NanoViricides (NYSE:NNVC) +100%. ReWalk Robotics (NASDAQ:RWLK) +56%. Spire (NYSE:SPIR) +30%. Corvus (NASDAQ:CRVS) +29%. Inotiv (NASDAQ:NOTV) +26%. Candel (NASDAQ:CADL) +23%. Rockley (NYSE:RKLY) +19%. Protagonist (NASDAQ:PTGX) +18%. indie Semiconductor (NAS...
Shares of Protagonist Therapeutics (NASDAQ: PTGX) were plunging 26.3% as of 3:39 p.m. EDT on Monday. The big decline came after the company announced that the U.S. Food and Drug Administration has placed a clinical hold on studies evaluating rusfertide. The FDA's clinical hold r...
Gainers: ZIVO Bioscience (NASDAQ:ZIVO) +98%. Edesa (NASDAQ:EDSA) +68%. Sentage (NASDAQ:SNTG) +21%. Viveve (NASDAQ:VIVE) +19%. Aterian (NASDAQ:ATER) +15%. Atea Pharmaceuticals (NASDAQ:AVIR) +12%. Corvus (NASDAQ:CRVS) +13%. Five Star (NASDAQ:FVE) +12%. BEST (NYSE:BEST) +10%. Petros Pharmaceutic...
News, Short Squeeze, Breakout and More Instantly...
Protagonist Therapeutics Inc. Company Name:
PTGX Stock Symbol:
NASDAQ Market:
Protagonist Therapeutics Inc. Website:
NEWARK, CA / ACCESSWIRE / August 1, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced publication of preclinical and phase 1 clinical data on JNJ-2113 in the journal Scientific Reports , a Nature publication and the 5th most-cited journal in the world, acc...
NEWARK, CA / ACCESSWIRE / August 1, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced publication of preclinical and phase 1 clinical data on JNJ-2113 in the journal Scientific Reports , a Nature publication and the 5th most-cited journal in the world, acc...
Dr. Yeilding joins Protagonist from Janssen Pharmaceutical Companies of Johnson & Johnson, where he held leadership roles in the immunology therapeutic area, bringing extensive experience in R&D and commercialization of novel therapeutics in the I&I space NEWARK, CA / ACCESSWIRE /...